Benign Prostatic Hyperplasia Surgical Treatment Market OverviewThe global benign prostatic hyperplasia surgical treatment ...
The global immuno-oncology market is projected to grow at a robust CAGR of approximately 21% over the next five years. This ...
Evidence suggests that adoption of oncology biosimilars in Medicare value-based payment models has produced substantial cost ...
Most men with low-grade prostate cancer have an excellent prognosis, with a five-year survival rate of more than 99%. But ...
Black men have a higher risk of prostate cancer. Surgery is sometimes the best treatment option for certain tumors. MSK ...
Follow-up overall survival, months, median (range) 96 (15-120) Follow-up PSA to recurrence or death, months, median (range) 55 (11-111) Follow-up PSA patients alive and recurrence-free, months, median ...
The safety evidence from TRAVERSE refers to men with confirmed low testosterone levels — below 300 nanograms per decilitre of ...
BOCA RATON, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s ...
The safety evidence from TRAVERSE refers to men with confirmed low testosterone levels — below 300 nanograms per decilitre of ...
Q: Last year, my 16-year-old son, who has asthma, had a lot of trouble when the wildfire smoke came into upper New York state ...
The role of highly selective androgen receptor (AR) targeted therapy in men with biochemically relapsed hormone sensitive prostate cancer. This is an ASCO Meeting Abstract from the 2015 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results